Truncated ADR58, derived by shortening full-length ADR58 from 71 bases to 31 bases, maintains comparable functional activity to its full-length counterpart. This compound acts as a potent and selective antagonist of human oncostatin M (OSM), effectively blocking OSM's interaction with the gp130 receptor and inhibiting OSM-mediated signaling. It is utilized in studying diseases related to rheumatoid arthritis [1].